US20100204498A1 - Agent having neurotrophic factor-like activity - Google Patents

Agent having neurotrophic factor-like activity Download PDF

Info

Publication number
US20100204498A1
US20100204498A1 US12/678,671 US67867108A US2010204498A1 US 20100204498 A1 US20100204498 A1 US 20100204498A1 US 67867108 A US67867108 A US 67867108A US 2010204498 A1 US2010204498 A1 US 2010204498A1
Authority
US
United States
Prior art keywords
trans
acid
ester
stressed
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/678,671
Other languages
English (en)
Inventor
Munekazu Iinuma
Shoei Furukawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nagoya Industrial Science Research Institute
Original Assignee
Nagoya Industrial Science Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nagoya Industrial Science Research Institute filed Critical Nagoya Industrial Science Research Institute
Assigned to NAGOYA INDUSTRIAL SCIENCE RESEARCH INSTITUTE reassignment NAGOYA INDUSTRIAL SCIENCE RESEARCH INSTITUTE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FURUKAWA, SHOEI, IINUMA, MUNEKAZU
Publication of US20100204498A1 publication Critical patent/US20100204498A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Definitions

  • the present invention relates to an agent having a neurotrophic factor-like activity, which is useful for nervous disorders such as neurodegenerative diseases and depression due to promotion of activation of nerve cells, by activating signal transmission with a neurotrophic factor-like activity of a nervous growth factor (NGF), a brain-derived neurotrophic factor (BDNF), and the like.
  • NGF nervous growth factor
  • BDNF brain-derived neurotrophic factor
  • a nerve cell is a cell having an information transmission function, and its damage emerges as serious loss of a cranial nerve function. Regeneration of an axon can hardly be expected in central nerves of a brain and spinal cord, and thus, when nerve cells have damage or degeneration, activation of the nerve cells is required.
  • a neurotrophic factor is indispensable for activation of nerve cells of central nerves and peripheral nerves such as differentiation of nerve cells, survival sustention, promotion of synapse functions, regeneration and restoration in damage of nerve cells, and the like.
  • a nervous growth factor (NGF), a brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), neurotrophin-4/5 (NT-4/5), and the like construct a neurotrophin family having 50% or more of sequence homology with a nervous growth factor (NGF) as a prototype.
  • NGF nervous growth factor
  • BDNF brain-derived neurotrophic factor
  • NT-3 neurotrophin-3
  • NT-4/5 neurotrophin-4/5
  • Activation of nerve cells is achieved by bonding a neurotrophic factor secreted outside the cells with a high-affinity receptor (Trks) to activate signal transmission through a MAP kinase (mitogen-activated protein (MAP) kinase) information transmission path that activates (phosphorylates) MAP kinases in the nerve cells, and controlling numerous genetic expressions through activation of CREB (c-AMP-response element binding protein) of a transcription factor, and the like.
  • MAP kinase mitogen-activated protein (MAP) kinase
  • CREB c-AMP-response element binding protein
  • BDNF brain-derived neurotrophic factors
  • Non-patent Document 1 On the basis of studies using a polymorphism of a brain-derived neurotrophic factor (BDNF), there are a report that a brain-derived neurotrophic factor (BDNF) is associated with Parkinson's disease (see Non-patent Document 1), a report that a brain-derived neurotrophic factor (BDNF) is associated with Alzheimer's disease (see Non-patent Document 2), a report that a brain-derived neurotrophic factor (BDNF) is associated with depression (see Non-patent Document 3), a report that a brain-derived neurotrophic factor (BDNF) is associated with bipolar depression (see Non-patent Document 4), and a report that a brain-derived neurotrophic factor (BDNF) is associated with anxiety disorder (see Non-patent Document 5).
  • BDNF brain-derived neurotrophic factor
  • Non-patent Document 6 a report that decrease in a synapse function of a genetically converted mouse having Huntington's disease is cured with administration of a brain-derived neurotrophic factor (BDNF) (see Non-patent Document 6), and a report that administration of a MAP kinase phosphorylation inhibitor provokes an antidepressant condition (see Non-patent Document 7).
  • BDNF brain-derived neurotrophic factor
  • Non-patent Document 7 a report that administration of a MAP kinase phosphorylation inhibitor provokes an antidepressant condition
  • neurotrophic factors are expected to have an effect as a therapeutic agent for nervous disorders.
  • neurotrophic factors are polymer proteins, they have a problem of having difficulty in reaching the brain since they cannot pass through a blood-brain barrier even if administered from a peripheral.
  • Patent Documents 1 and 2 an agent having a neurotrophic factor-like activity containing a compound having a predetermined general formula has been proposed (Patent Documents 1 and 2).
  • the agents having neurotrophic factor-like activities or the production and secretion accelerators of neurotrophic factors described in Patent Documents 1 to 5 do not contain fatty acids or fatty acid esters as active ingredients.
  • an active ingredient disclosed with a pharmacological activity of nerve regeneration is (2R)-2-propyloctanoic acid.
  • the pharmaceutical agent for preventing and curing neurodegenerative diseases described in Patent Document 7 contains a saturated fatty acid having 10 or less carbon atoms (C10), an unsaturated fatty acid or saturated fatty acid ester each having 5 carbon atoms (C5) as an active ingredient.
  • An object of the present invention is to provide a pharmaceutical agent having high safety and a neurotrophic factor-like activity, which contains a predetermined fatty acid or fatty acid ester as an active ingredient.
  • a gist of the present invention lies in an agent having a neurotrophic factor-like activity, containing, as an active ingredient, anyone compound included in fatty acids each having 8 carbon atoms (C8) or having 10 carbon atoms (C10) to 12 carbon atoms (C12) or fatty acid esters thereof, such as n-octanoic acid methyl ester, n-octanoic acid ethyl ester, 3,7-dimethyloctanoic acid ethyl ester, or geranic acid ethyl ester, each of which has 8 carbon atoms (C8), decanoic acid methyl ester, decanoic acid ethyl ester, trans-2-decenoic acid, trans-2-decenoic acid methyl ester, trans-2-decenoic acid ethyl ester, trans-2-decenoic acid-2-decenyl ester, trans-2-decenoic acid cyclohexyl este
  • a gist of the present invention lies in the agent having a neurotrophic factor-like activity for a preventive and therapeutic agent for a nervous disorder.
  • the nervous disorder may be a neurodegenerative disease such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, progressive supranuclear palsy (PSP), or diabetic neuropathy.
  • the nervous disorder may be a mental disease, and the mental disease may be depression or anxiety disorder (neurosis).
  • a gist of the present invention lies in trans-2-decenoic acid-2-decenyl ester, having a neurotrophic factor-like activity.
  • a gist of the present invention lies in trans-2-decenoic acid cyclohexyl ester, having a neurotrophic factor-like activity.
  • the agent having a neurotrophic factor-like activity of the present invention is useful as a preventive and therapeutic agent for a nervous disorder, which has high safety and activates signal transmission through a MAP kinase information transmission path.
  • the agent is useful as a preventive and improving agent for a neurodegenerative disease such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, progressive supranuclear palsy (PSP), or diabetic neuropathy in nervous disorders.
  • the agent is useful as a preventive and improving agent for a mental disease in the nervous disorder.
  • the agent is useful as a preventive and improving agent for depression or anxiety disorder (neurosis) in the mental disease.
  • the agent can be expected to have an immediate antidepressant effect and antianxiety effect as a preventive and improving agent for depression or anxiety disorder (neurosis).
  • FIG. 1 is a graph showing ratios of phosphorylated MAP kinases to MAP kinases of compounds 1, 2, 3, 6, 7, 8, 11, 12 and 13 in Example 1.
  • FIG. 2 is a graph showing ratios of phosphorylated MAP kinases to MAP kinases of compounds 16, 17, 18, 21, 22, 23, 36, 37 and 38 in Example 1.
  • FIG. 3 is a graph showing ratios of phosphorylated MAP kinases to MAP kinases of compounds 47, 48, 53, 54, 62, 63, 77 and 78 in Example 1.
  • FIG. 4 is a graph of a burying the glass-marbles test of comparing the numbers of buried glass marbles between stressed examples and non-stressed examples of the “stressed 3 week-administration groups” in Example 2.
  • FIG. 5 is a graph of a burying the glass-marbles test of comparing the numbers of burying glass marbles between stressed examples and non-stressed examples of the “stressed 1 week-administration groups” in Example 2.
  • FIG. 6 is a graph of a tail suspension test of comparing immobility times between stressed examples and non-stressed examples of the “stressed 3 week-administration groups” in Example 2.
  • FIG. 7 is a graph of a tail suspension test of comparing immobility times between stressed examples and non-stressed examples of the “stressed 1 week-administration groups” in Example 2.
  • FIG. 8 is a graph of an elevated plus maze test of comparing times for being in open arms between stressed examples and non-stressed examples of the “stressed 3 week-administration groups” in Example 2.
  • FIG. 9 is a graph of an elevated plus maze test of comparing the numbers of times of entering closed arms between stressed examples and non-stressed examples of the “stressed 3 week-administration groups” in Example 2.
  • FIG. 10 is a graph of an elevated plus maze test of comparing times for being in open arms between stressed examples and non-stressed examples of the “stressed 1 week-administration groups” in Example 2.
  • FIG. 11 is a graph of an elevated plus maze test of comparing the numbers of times of entering closed arms between stressed examples and non-stressed examples of the “stressed 1 week-administration groups” in Example 2.
  • FIG. 12 is a graph comparing gaps of body weights between stressed examples obtained by administering the compound 8 and applying stress for 3 weeks and non-stressed examples in Example 3.
  • FIG. 13 is a graph comparing phosphorylated MAP kinase amounts in cortexes of frontal lobes between stressed examples obtained by administering the compound 8 and applying stress for 3 weeks and non-stressed examples in Example 4.
  • FIG. 14 is a graph comparing phosphorylated MAP kinase amounts in hippocampi between stressed examples obtained by administering the compound 8 and applying stress for 3 weeks and non-stressed examples in Example 4.
  • FIG. 15 is a graph comparing expression amounts of mRNAs of BDNF, NT-3, NGF and GR in cortexes of the frontal lobes between stressed examples obtained by administering the compound 8 and applying stress for 3 weeks and non-stressed examples in Example 5.
  • FIG. 16 is a graph comparing expression amounts of mRNAs of BDNF, NT-3, NGF and GR in hippocampi between stressed examples obtained by administering the compound 8 and applying stress for 3 weeks and non-stressed examples in Example 5.
  • FIG. 17 is a graph of a burying the glass-marbles test of comparing the numbers of buried glass marbles between stressed examples and non-stressed examples of the “non-administration groups after completion of stress” in Example 6.
  • FIG. 18 is a graph of a burying the glass-marbles test of comparing the numbers of buried glass marbles between stressed examples and non-stressed examples of the “1 week-administration groups after completion of stress” in Example 6.
  • FIG. 19 is a graph of a burying the glass-marbles test of comparing the numbers of buried glass marbles between stressed examples and non-stressed examples of the “2 week-administration groups after completion of stress” in Example 6.
  • FIG. 20 is a graph of a tail suspension test of comparing immobility times between stressed examples and non-stressed examples of the “non-administration groups after completion of stress” in Example 6.
  • FIG. 21 is a graph of a tail suspension test of comparing immobility times between stressed examples and non-stressed examples of the “1 week-administration groups after completion of stress” in Example 6.
  • FIG. 22 is a graph of a tail suspension test of comparing immobility times between stressed examples and non-stressed examples of the “2 week-administration groups after completion of stress” in Example 6.
  • FIG. 23 is a graph of an elevated plus maze test of comparing times for being in open arms between stressed examples and non-stressed examples of the “non-administration groups after completion of stress” in Example 6.
  • FIG. 24 is a graph of an elevated plus maze test of comparing the numbers of times of entering closed arms between stressed examples and non-stressed examples of the “non-administration groups after completion of stress” in Example 6.
  • FIG. 25 is a graph of an elevated plus maze test of comparing times for being in open arms between stressed examples and non-stressed examples of the “1 week-administration groups after completion of stress” in Example 6.
  • FIG. 26 is a graph of an elevated plus maze test of comparing the numbers of times of entering closed arms between stressed examples and non-stressed examples of the “1 week-administration groups after completion of stress” in Example 6.
  • FIG. 27 is a graph of an elevated plus maze test of comparing times for being in open arms between stressed examples and non-stressed examples of the “2 week-administration groups after completion of stress” in Example 6.
  • FIG. 28 is a graph of an elevated plus maze test of comparing the numbers of times of entering closed arms between stressed examples and non-stressed examples of the “2 week-administration groups after completion of stress” in Example 6.
  • FIG. 29 is a graph comparing gaps of body weights between stressed examples immediately after applying stress for 3 weeks and non-stressed examples in Example 7.
  • FIG. 30 is a graph comparing gaps of body weights between stressed examples obtained by administering the compound 8 for 1 week after applying stress for 3 weeks and non-stressed examples in Example 7.
  • FIG. 31 show an evaluation method of a behavior test (behavior assessment) (A) and a graph of a tail suspension test (B) comparing effects on antidepressant symptoms with the compound 8 and fluvoxamine in Example 8.
  • FIG. 32 are graphs of a voluntary alternation behavior test (Y-maze test) of mice administered with trimethyltin in Example 9.
  • FIG. 32A is a graph showing ratios of alternation behavior (%) of respective test groups
  • FIG. 32B is a graph showing the numbers of total arm selection (total arm entries) of respective test groups.
  • FIG. 33 are graphs of a novel object recognition test of mice in Example 10.
  • FIG. 33A is a graph showing time for the mice to explore a “familiar object” and a “novel object” (exploration time)
  • FIG. 33B is a graph showing recognition indices.
  • a fatty acid ester that is an active ingredient of the agent having a neurotrophic factor-like activity of the present invention can be produced in known methods. For examples, it can be produced by the Fischer esterification method in which a fatty acid and an alcohol are reacted in the presence of an acid catalyst, or a transesterification method.
  • acyl halide can be produced by substituting a hydroxyl group of a fatty acid to a halogen with a thionyl chloride, sulfiryl chloride, phosphorus trichloride, phosphorus pentachloride, oxalyl chloride, phosphoric trichloride, or the like to give acyl halide and reacting the acyl halide with an alcohol.
  • the produced fatty acid ester can be isolated using known separation and purification techniques such as extraction, partition, and column chromatography, after completion of the reaction.
  • the fatty acid or the fatty acid ester is any one compound included in fatty acids each having 8 carbon atoms (C8) or having 10 carbon atoms (C10) to 12 carbon atoms (C12) or fatty acid esters thereof, such as n-octanoic acid methyl ester, n-octanoic acid ethyl ester, 3,7-dimethyloctanoic acid ethyl ester, or geranic acid ethyl ester, each of which has 8 carbon atoms (C8), decanoic acid methyl ester, decanoic acid ethyl ester, trans-2-decenoic acid, trans-2-decenoic acid methyl ester, trans-2-decenoic acid ethyl ester, trans-2-decenoic acid-2-decenyl ester, trans-2-decenoic acid cyclohexyl ester, trans-2-decenoic acid octyl ester
  • the fatty acids or fatty acid esters can also be isolated fatty acids or fatty acid esters, or pharmaceutically acceptable salts thereof or prodrugs thereof.
  • the salts include alkali metal salts such as sodium salt and potassium salt; alkali earth metal salts such as magnesium salt and calcium salt; inorganic acids such as hydrochloric acid, sulfuric acid, phosphoric acid, and hydrobromic acid; alkanol amines such as ammonium salt and triethanol amine; and acid addition salts of organic acids such as acetic acid, formic acid, fumaric acid, and oxalic acid.
  • the fatty acids or fatty acid esters can be solvates of the fatty acids or fatty acid esters. Examples of the solvates include hydrates and alcoholates.
  • the agent having a neurotrophic factor-like activity is useful for prevention and treatment of nervous disorders.
  • the nervous disorder refers to a clinical condition of damaging functions of nerve cells due to degeneration and cell death of the nerve cells, and includes neurodegenerative diseases and mental diseases.
  • the neurodegenerative diseases refer to Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, progressive supranuclear palsy (PSP), diabetic neuropathy, etc.
  • the mental diseases refer to depression (including bipolar depression), anxiety disorder (neurosis), integration disorder syndrome, etc.
  • the agent When the agent is used for depression, it takes at least 3 to 4 weeks until there appear effects of conventionally existing depression therapeutic agents such as a tricyclic antidepressant, a tetracyclic antidepressant, a selective serotonin reuptake inhibitor (SSRI), a serotonin noradrenalin reuptake inhibitor (SNRI), and the like, and these agents had to be taken periodically during this term; however, the agent having a neurotrophic factor-like activity of the present invention can be expected to have immediate affectivity as compared to existing medical drugs.
  • An administration form of the agent having a neurotrophic factor-like activity as a medical drug is not particularly limited, and may be any administration form of oral and parenteral routes.
  • a suitable dosage form can be employed according to an administration form, and the agent can be formed into various preparations such as injectable agents, or oral agents (e.g., capsules, tablets, granules, sprays, pills, subtle granules, etc.), rectal administration agents, oleagenous suppositories, and aqueous suppositories.
  • Various preparations are prepared by adding vehicles, binding agents, brighteners, disintegrating agents, surfactants, fluidity accelerators, and the like, which are pharmaceutically acceptable and generally used.
  • the vehicles include lactose, fructose, glucose, cornstarch, sorbit, crystalline cellulose.
  • the binding agents include methyl cellulose, ethyl cellulose, gum arabic, gelatin, hydroxypropyl cellulose, and polyvinyl pyrrolidone.
  • the brighteners include talc, magnesium stearate, polyethylene glycol, and curing vegetable oils.
  • the disintegrating agents include starch, sodium alginate, gelatin, calcium carbonate, calcium citrate, dextrin, magnesium carbonate, and synthetic magnesium silicate.
  • surfactants include sodium lauryl sulfate, soybean lecithin, sucrose fatty acid esters, and polysorbate 80.
  • fluidity accelerators include light anhydrous silicic acid, a dry aluminum hydroxide gel, synthetic aluminum silicate, and magnesium silicate.
  • other additives include a syrup, vaseline, glycerin, ethanol, propylene glycol, citric acid, sodium chloride, sodium nitrite, and sodium phosphate.
  • An administration dose of the agent having a neurotrophic factor-like activity can be suitably increased in consideration of a usage, an age, a sex and a degree of a symptom of a patient, and the like, and is generally 1 to 1000 mg, and preferably 5 to 300 mg, per day for an adult, and such a dose can be administered once a day or dividedly administered several times a day.
  • Decanoic acid was dissolved in thionyl chloride (10 ml) and treated in water bath for 3 hours to distill off excess thionyl chloride. Methanol (30 ml) was added to chloride of decanoic acid and refluxed in water bath for 2 hours. After cooling, the reaction mixture was added to 1N HCl (80 ml) to be acidic and distributed with ethyl acetate (hereinafter expressed as “EtOAc”). The distributed liquid was purified with column chromatography (developing solvent: n-hexane (C 6 H 14 )-EtOAc (3:1)) after concentration, and decanoic acid methyl ester shown in the following was isolated.
  • EtOAc ethyl acetate
  • Decanoic acid was dissolved in thionyl chloride (10 ml) and treated in water bath for 3 hours to distill off excess thionyl chloride. Ethanol (30 ml) was added to chloride of decanoic acid and refluxed in water bath for 2 hours. After cooling, the reaction mixture was added to 1N HCl (80 ml) to be acidic and distributed with EtOAc. The distributed liquid was purified with column chromatography (developing solvent: C 6 H 14 -EtOAc (3:1)) after concentration, and decanoic acid ethyl ester shown in the following was isolated.
  • Trans-2-decenoic acid was dissolved in thionyl chloride (10 ml) and treated in water bath for 3 hours to distill off excess thionyl chloride. Methanol (30 ml) was added to chloride of trans-2-decenic acid and refluxed in water bath for 2 hours. After cooling, the reaction mixture was added to 1N HCl (80 ml) to be acidic and distributed with EtOAc. The distributed liquid was purified with column chromatography (developing solvent: C 6 H 14 -EtOAc (3:1)) after concentration, and trans-2-decenoic acid methyl ester shown in the following was isolated.
  • Trans-2-decenoic acid was dissolved in thionyl chloride (10 ml) and treated in water bath for 3 hours to distill off excess thionyl chloride. Ethanol (30 ml) was added to chloride of trans-2-decenic acid and refluxed in water bath for 2 hours. After cooling, the reaction mixture was added to 1N HCl (80 ml) to be acidic and distributed with EtOAc. The distributed liquid was purified with column chromatography (developing solvent: C 6 H 14 -EtOAc (3:1)) after concentration, and trans-2-decenoic acid ethyl ester shown in the following was isolated.
  • Trans-9-decenoic acid was dissolved in thionyl chloride (10 ml) and treated in water bath for 3 hours to distill off excess thionyl chloride. Methanol (30 ml) was added to chloride of trans-9-decenic acid and refluxed in water bath for 2 hours. After cooling, the reaction mixture was added to 1N HCl (80 ml) to be acidic and distributed with EtOAc. The distributed liquid was purified with column chromatography (developing solvent: C 6 H 14 -EtOAc (3:1)) after concentration, and trans-9-decenoic acid methyl ester shown in the following was isolated.
  • Trans-9-decenoic acid was dissolved in thionyl chloride (10 ml) and treated in water bath for 3 hours to distill off excess thionyl chloride. Ethanol (30 ml) was added to chloride of trans-9-decenic acid and refluxed in water bath for 2 hours. After cooling, the reaction mixture was added to 1N HCl (80 ml) to be acidic and distributed with EtOAc. The distributed liquid was purified with column chromatography (developing solvent: C 6 H 14 -EtOAc (3:1)) after concentration, and trans-9-decenoic acid ethyl ester shown in the following was isolated.
  • Dodecanoic acid was dissolved in thionyl chloride (10 ml) and treated in water bath for 3 hours to distill off excess thionyl chloride. Methanol (30 ml) was added to chloride of dodecanoic acid and refluxed in water bath for 2 hours. After cooling, the reaction mixture was added to 1N HCl (80 ml) to be acidic and distributed with EtOAc. The distributed liquid was purified with column chromatography (developing solvent: C 6 H 14 -EtOAc (3:1)) after concentration, and dodecanoic acid methyl ester shown in the following was isolated.
  • Dodecanoic acid was dissolved in thionyl chloride (10 ml) and treated in water bath for 3 hours to distill off excess thionyl chloride. Ethanol (30 ml) was added to chloride of dodecanoic acid and refluxed in water bath for 2 hours. After cooling, the reaction mixture was added to 1N HCl (80 ml) to be acidic and distributed with EtOAc. The distributed liquid was purified with column chromatography (developing solvent: C 6 H 14 -EtOAc (3:1)) after concentration, and dodecanoic acid ethyl ester shown in the following was isolated.
  • Trans-10-undecenoic acid was dissolved in thionyl chloride (10 ml) and treated in water bath for 3 hours to distill off excess thionyl chloride. Methanol (30 ml) was added to chloride of trans-10-undecenic acid and refluxed in water bath for 2 hours. After cooling, the reaction mixture was added to 1N HCl (80 ml) to be acidic and distributed with EtOAc. The distributed liquid was purified with column chromatography (developing solvent: C 6 H 14 -EtOAc (3:1)) after concentration, and trans-10-undecenoic acid methyl ester shown in the following was isolated.
  • Trans-10-undecenoic acid was dissolved in thionyl chloride (10 ml) and treated in water bath for 3 hours to distill off excess thionyl chloride. Ethanol (30 ml) was added to chloride of trans-10-undecenic acid and refluxed in water bath for 2 hours. After cooling, the reaction mixture was added to 1N HCl (80 ml) to be acidic and distributed with EtOAc. The distributed liquid was purified with column chromatography (developing solvent: C 6 H 14 -EtOAc (3:1)) after concentration, and trans-10-undecenoic acid ethyl ester shown in the following was isolated.
  • n-octanoic acid was dissolved in thionyl chloride (10 ml) and treated in water bath for 3 hours to distill off excess thionyl chloride. Methanol (30 ml) was added to chloride of n-octanoic acid and refluxed in water bath for 2 hours. After cooling, the reaction mixture was added to 1N HCl (80 ml) to be acidic and distributed with EtOAc. The distributed liquid was purified with column chromatography (developing solvent: C 6 H 14 -EtOAc (3:1)) after concentration, and n-octanoic acid methyl ester shown in the following was isolated.
  • n-octanoic acid was dissolved in thionyl chloride (10 ml) and treated in water bath for 3 hours to distill off excess thionyl chloride. Ethanol (30 ml) was added to chloride of n-octanoic acid and refluxed in water bath for 2 hours. After cooling, the reaction mixture was added to 1N HCl (80 ml) to be acidic and distributed with EtOAc. The distributed liquid was purified with column chromatography (developing solvent: C 6 H 14 -EtOAc (3:1)) after concentration, and n-octanoic acid ethyl ester shown in the following was isolated.
  • Trans-2-decenoic acid was dissolved in thionyl chloride (10 ml) and treated in water bath for 3 hours to distill off excess thionyl chloride.
  • Trans-2-decen-1-ol (30 ml) was added to chloride of trans-2-decenoic acid and refluxed in water bath for 2 hours. After cooling, the reaction mixture was added to 1N HCl (80 ml) to be acidic and distributed with EtOAc. The distributed liquid was purified with column chromatography (developing solvent: C 6 H 14 -EtOAc (3:1)) after concentration, and trans-2-decenoic acid-trans-2-decenyl ester shown in the following was isolated.
  • Trans-2-decenoic acid was dissolved in thionyl chloride (10 ml) and treated in water bath for 3 hours to distill off excess thionyl chloride. Cyclohexanol (30 ml) was added to chloride of trans-2-decenoic acid and refluxed in water bath for 2 hours. After cooling, the reaction mixture was added to 1N HCl (80 ml) to be acidic and distributed with EtOAc. The distributed liquid was purified with column chromatography (developing solvent: C 6 H 14 -EtOAc (3:1)) after concentration, and trans-2-decenoic acid cyclohexyl ester shown in the following was isolated.
  • Trans-2-decenoic acid was dissolved in thionyl chloride (10 ml) and treated in water bath for 3 hours to distill off excess thionyl chloride.
  • 1-octanol (30 ml) was added to chloride of trans-2-decenoic acid and refluxed in water bath for 2 hours. After cooling, the reaction mixture was added to 1N HCl (80 ml) to be acidic and distributed with EtOAc.
  • the distributed liquid was purified with column chromatography (developing solvent: C 6 H 14 -EtOAc (3:1)) after concentration, and trans-2-decenoic acid octyl ester shown in the following was isolated.
  • Trans-2-decenoic acid was dissolved in thionyl chloride (10 ml) and treated in water bath for 3 hours to distill off excess thionyl chloride.
  • An isopropyl alcohol (30 ml) was added to chloride of trans-2-decenoic acid and refluxed in water bath for 2 hours. After cooling, the reaction mixture was added to 1N HCl (80 ml) to be acidic and distributed with EtOAc.
  • the distributed liquid was purified with column chromatography (developing solvent: C 6 H 14 -EtOAc (3:1)) after concentration, and trans-2-decenoic acid isopropyl ester shown in the following was isolated.
  • Trans-3-decenoic acid (Wako Pure Chemical Industries, Ltd.) was dissolved in thionyl chloride (10 ml) and treated in water bath for 3 hours to distill off excess thionyl chloride. Methanol (30 ml) was added to chloride of trans-3-decenoic acid and refluxed in water bath for 2 hours. After cooling, the reaction mixture was added to 1N HCl (80 ml) to be acidic and distributed with EtOAc. The distributed liquid was purified with column chromatography (developing solvent: C 6 H 14 -EtOAc (3:1)) after concentration, and trans-3-decenoic acid methyl ester shown in the following was isolated.
  • Trans-3-decenoic acid (Wako Pure Chemical Industries, Ltd.) was dissolved in thionyl chloride (10 ml) and treated in water bath for 3 hours to distill off excess thionyl chloride. Ethanol (30 ml) was added to chloride of trans-3-decenoic acid and refluxed in water bath for 2 hours. After cooling, the reaction mixture was added to 1N HCl (80 ml) to be acidic and distributed with EtOAc. The distributed liquid was purified with column chromatography (developing solvent: C 6 H 14 -EtOAc (3:1)) after concentration, and trans-3-decenoic acid ethyl ester shown in the following was isolated.
  • Geranic acid (Wako Pure Chemical Industries, Ltd.) was dissolved in thionyl chloride (10 ml) and treated in water bath for 3 hours to distill off excess thionyl chloride. Ethanol (30 ml) was added to chloride of geranic acid and refluxed in water bath for 2 hours. After cooling, the reaction mixture was added to 1N HCl (80 ml) to be acidic and distributed with EtOAc. The distributed liquid was purified with column chromatography (developing solvent: C 6 H 14 -EtOAc (3:1)) after concentration, and geranic acid ethyl ester shown in the following was isolated.
  • 3,7-dimethyloctanoic acid was dissolved in thionyl chloride (10 ml) and treated in water bath for 3 hours to distill off excess thionyl chloride. Ethanol (30 ml) was added to chloride of 3,7-dimethyloctanoic acid and refluxed in water bath for 2 hours. After cooling, the reaction mixture was added to 1N HCl (80 ml) to be acidic and distributed with EtOAc. The distributed liquid was purified with column chromatography (developing solvent: C 6 H 14 -EtOAc (3:1)) after concentration, and the 3,7-dimethyloctanoic acid ethyl ester shown in the following was isolated. 3,7-dimethyloctanoic acid was obtained by contact reduction of geranic acid.
  • Activation of MAP kinases was measured on respective compounds in Table 1 including the compound obtained in Production Example with western immunoblotting as follows.
  • Nerve cells were dispersed from a cerebral cortex of a 17-day-old fetal rat and the nerve cells were cultured in a Dulbecco's modified eagle medium (DMEM) containing 5% fetal bovine serum for 1 day.
  • DMEM Dulbecco's modified eagle medium
  • a culture solution was exchanged to a serum-free medium (B27 supplement added Neurobasal, Invitrogen Corporation), and the nerve cells were cultured in a culture petri dish coated with polyornithine at a density of 20,000 to 40,000 cells/cm 2 .
  • B27 serum-free medium
  • polyornithine three days later, each of the compounds in Table 1 was added thereto, and culture for 30 minutes was continued.
  • the protein was transcribed to a PVDF membrane from the gel after electrophoresis, and western immunoblotting was carried out using the primary antibodies: an anti-MAP kinase antibody (Cell Signaling Technology, Inc.) and an antiphosphorylated MAP kinase antibody (Cell Signaling Technology, Inc.), respectively. Subsequently, an enzyme activity was subjected to color development by being reacted with the secondary antibody: an alkaline phosphatase labeled anti-rabbit IgG antibody (Promega KK) to measure MAP kinases and phosphorylated MAP kinases. In addition, each compound was dissolved in 0.1% DMSO and adjusted to have a concentration of 500 ⁇ g/ml. A control was added with a phosphoric acid buffer containing 0.1% DMSO in the same amount as the compound.
  • the above obtained concentration measurement of the electrophoresis gel band was digitalized by calculating an intensity with Image J (BioArts International, Inc.).
  • the numerical value of MAP kinases of each compound was divided by the numerical value of the control's MAP kinases, and the numerical value of phosphorylated MAP kinases of each compound was divided by the numerical value of the control's phosphorylated MAP kinases to find a ratio of the MAP kinases of each compound to the control and a ratio of the phosphorylated MAP kinases of the each compound to the control.
  • trans-2-decenoic acid esters such as any of the compounds having different alkoxy groups (compound Nos. 7, 8, 47, 48, 53 and 54) showed twice or more numerical values, and high MAP kinase activation (phosphorylation) effects were shown.
  • trans-2-decenic acid ethyl ester was as high as 11 times, and secondarily, trans-2-decenic acid methyl ester was 6 times.
  • decanoic acid methyl ester decanoic acid ethyl ester, trans-2-decenoic acid, trans-9-decenoic acid methyl ester, trans-9-decenoic acid ethyl ester, trans-10-undecenoic acid methyl ester, trans-10-undecenoic acid ethyl ester, geranic acid ethyl ester and 3,7-dimethyloctanoic acid ethyl ester showed high activities.
  • mice under established chronic mild stress were used for a depression and anxiety disorder-like model animal. Stress was applied as follows. 7-week-old male ddY strain mice fed in one cage for 4 mice were used and first subjected to forced swimming for 15 minutes. Then, the mice were fed in a sloped cage for 2 days, and then rested in a normal cage for 1 day. Then, the mice were fed in a dirt cage moisturized with 200 mL of water for 1 day and then rested in a normal cage for 1 day. Then, the mice were fed in a rotational cage that rotated at 180 rpm for 1 day, and then rested in a normal cage for 1 day.
  • a phosphoric acid buffer containing 0.1% DMSO (controls were expressed as “PBS” or “0 ⁇ g/kg” in the figure shown below) was administered in an amount of 0.25 mL to each of a stressed example and a non-stressed example.
  • mice The behavior test of mice was performed on each of the following: an administration group to which the compound 8 was administered at the same time as stress for 3 weeks and an administration group to which the compound 8 was administered for 3 weeks without stress (hereinafter referred to as the “stressed 3 week-administration groups”); and an administration group to which the compound 8 was administered at the same time as stress for 1 week and an administration group to which the compound 8 was administered for 1 week without stress (hereinafter referred to as the “stressed 1 week-administration groups”). Additionally, an example in which stress was applied to a mouse may be referred to as a stressed example, and an example in which stress was not applied to a mouse maybe referred to as a non-stressed example. Further, a significance test was performed on the results of Examples 1 to 7 in a Student's t-test.
  • Tips were bedded so as to have a height of 5 cm in a box with 30 m 2 and 25 glass marbles (1.6 cm in diameter) were placed thereon at 5 cm-interval and behaviors of mice were observed.
  • the number of buried glass marbles was found by counting each glass marble that was buried in 2 ⁇ 3 or more from visual observation from just above after 15 minutes as one count. The test was performed for 3 hours. Since a mouse under stress having an anxiety symptom (condition) takes such a behavior as burying glass marbles, a level of the anxiety symptom can be evaluated from the number of buried glass marbles.
  • FIGS. 4 and 5 show the results.
  • mice had a significant difference between a stressed example and a non-stressed example of controls (PBS) in any of “the stressed 3 week-administration group” and “the stressed 1 week-administration group”; on the contrary, there was no significant difference between a stressed example and a non-stressed example in each administration example of the administration groups of the compound 8 (see FIGS. 4 and 5 ), and the compound 8 suppressed an anxiety symptom. From the result of “the stressed 1 week-administration group”, the compound 8 is considered to immediately act on the anxiety symptom.
  • PBS non-stressed example of controls
  • FIGS. 6 and 7 show the results.
  • mice had a significant difference between a stressed example and a non-stressed example of controls (PBS) in any of “the stressed 3 week-administration groups” and “the stressed 1 week-administration groups”; on the contrary, there was no significant difference between a stressed example and a non-stressed example in each administration example of the administration groups of the compound 8 (see FIGS. 6 and 7 ), and the compound 8 suppressed a depressive symptom. From the result of “the stressed 1 week-administration group”, the compound 8 is considered to immediately act on the depressive symptom.
  • PBS non-stressed example of controls
  • FIG. 12 shows the result.
  • FIG. 12 reveals that a weight of a non-stressed example of the control (PBS) increased, and on the other hand, a weight of a stressed example significantly decreased due to depressive and anxiety symptoms.
  • ratios of the weight decreases in stressed examples of the compound 8 administration groups were less due to a suppression effect of the compound 8 on depressive and anxiety symptoms as compared to the control (PBS), and there was no significant difference between a stressed example and a non-stressed example in the 500 ⁇ g/kg administration group and an effect on the body weights was not recognized.
  • mice administered with the compound 8 in doses of 0, 20, 100 and 500 ⁇ g/kg respectively at the same time as stress and non-stressed mice administered with only a phosphoric acid buffer containing 0.1% DMSO were sacrificed and the cortexes of frontal lobes and hippocampi were excised respectively, and thereto were added RIPA buffers in 19 times of an amount of each wet weight.
  • Proteins were then transcribed to a PVDF membrane from the gel and the membrane after transcription was immersed in a block liquid (TBS containing 5% skimmed milk) for 1 hour, and reacted with primary antibodies: an anti-MAP kinase antibody (Cell Signaling Technology, Inc.) and an antiphosphorylated MAP kinase antibody (Cell Signaling Technology, Inc.) overnight, and further reacted with the secondary antibody: an alkaline phosphatase labeled anti-rabbit IgG antibody (Promega KK) for 1 hour.
  • TBS block liquid
  • primary antibodies an anti-MAP kinase antibody
  • an antiphosphorylated MAP kinase antibody Cell Signaling Technology, Inc.
  • secondary antibody an alkaline phosphatase labeled anti-rabbit IgG antibody (Promega KK) for 1 hour.
  • a D1G3 buffer was used as the substrate of an alkaline phosphatase and incubated with a liquid obtained by adding nitroblue tetrazolium (NBT) and 5-bromo-4-chloro-3-indolylphosphate p-toluidine salt (BCIP) for several minutes to develop a color.
  • NBT nitroblue tetrazolium
  • BCIP 5-bromo-4-chloro-3-indolylphosphate p-toluidine salt
  • an intensity was calculated with Image J (BioArts International, Inc.) to find a phosphorylated MAP kinase amount of each of the compound 8 administration groups to a phosphorylated MAP kinase amount in a non-stressed example.
  • FIGS. 13 and 14 show the results.
  • FIGS. 13 and 14 reveal that the phosphorylated MAP kinase amount of the control (0 ⁇ g/kg) significantly decreased in both of the cortex of frontal lobe and hippocampus as compared to a non-stressed example.
  • the compound 8 administration groups had an administration example in which the phosphorylated MAP kinase amount significantly increased as compared to the control (0 ⁇ g/kg) and the compound 8 promoted activation (phosphorylation) of the MAP kinase.
  • BDNF brain-derived neurotrophic factor
  • NT-3 neurotrophin-3
  • NNF nervous growth factor
  • GR glucocorticoid receptor
  • mice administered with the compound 8 in each of the amounts of 0, 20, 100 and 500 ⁇ g/kg, at the same time as stress, and non-stressed mice administered with only a phosphoric acid buffer containing 0.1% DMSO were sacrificed and the cortexes of frontal lobes and hippocampi were excised respectively, and thereto were added TriZol.
  • the both tissues were crashed with a homogenizer respectively, chloroform was then added thereto, and the mixture was centrifuged at 15000 rpm for 15 minutes to take out the aqueous phase. This aqueous phase was added with isopropanol and centrifuged at 15000 rpm for 15 minutes.
  • RNA sample was washed with 70% ethanol, dried and then dissolved in TE to form a total RNA sample.
  • annealing was performed by adding a CDS primer (oligo dt primer) solution to 0.5 ⁇ g of the total RNA sample to react at 72° C. for 2 minutes. Then, a 5 ⁇ first strand buffer, DTT, dNTP and a reverse transcriptase were added thereto to react at 42° C. for 60 minutes. Thereto was added TE and reacted at 72° C. for 7 minutes to form a cDNA sample.
  • CDS primer oligo dt primer
  • a PCR reaction was carried out by adding a mixed solution containing cDNA, Taq polymerase and primers (respective primers having sequences (10 to 20) specific to BDNF, NGF, NT-3 and GR).
  • a treatment was carried out at 94° C. for 5 minutes in initiation, modification at 94° C. for 45 seconds, annealing at 61° C. for 45 seconds, and elongation at 72° C. for 30 seconds were performed as one cycle, 28 cycles were repeated for BDNF, 30 cycles were repeated for NT-3, 34 to 37 cycles were repeated for NGF, and 37 cycles were repeated for GR.
  • an elongation reaction was performed at 72° C. for 7 minutes.
  • Example 2 is a behavior test in which the compound 8 was administered to a mouse as well as stress was applied and a suppression effect of the compound 8 on depressive and anxiety symptoms of the mouse was examined.
  • the present example is a behavior test in which only stress was applied for 3 weeks without administering the compound 8 and stress was completed and a therapeutic effect of the compound 8 on depressive and anxiety symptoms of a mouse after removing stress was examined. Stress was applied to a mouse in the same manner as in Example 2.
  • non-administration groups after completion of stress groups without administering the compound 8 immediately after completion of stress for 3 weeks and groups without administering the compound 8 with no stress from the start
  • non-administration groups after completion of stress a group administered with the compound 8 for 1 week after completion of stress and a group administered with the compound 8 for 1 week in the same manner as the former group with no stress from the start
  • 1 week-administration groups after completion of stress a group administered with the compound 8 for 2 weeks after completion of stress and a group administered with the compound 8 for 2 weeks in the same manner as the former group with no stress from the start
  • mice there were significant differences between a stressed example and a non-stressed example of controls (0 ⁇ g/kg) of “the non-administration groups after completion of stress” and between a stressed example and a non-stressed example of the compound 8 administration groups (see FIGS. 17 , 20 and 23 ). Although doses are described in FIGS. 17 , 20 , 23 and 24 showing “the non-administration groups after completion of stress”, the compound 8 was not administered in any of the groups as described above, and mice corresponding to each of the administration groups, “the 1 week-administration groups after completion of stress” and “the 2 week-administration groups after completion of stress” are only shown.
  • mice had a significant difference between a stressed example and a non-stressed example of controls (0 ⁇ g/kg) in “the 1 week-administration groups after completion of stress”, but there was no significant difference between a stressed example and a non-stressed example in 500 ⁇ g/kg administration examples (see FIG. 21 ), and the compound 8 exhibited an immediate therapeutic effect on an anxiety symptom after removing stress.
  • the immobility times of mice had a significant difference between a stressed example and a non-stressed example of controls (0 ⁇ g/kg) in “the 2 week-administration groups after completion of stress”, but there was no significant difference between a stressed example and a non-stressed example in all administration examples (see FIG. 22 ), and the compound 8 exhibited a high therapeutic effect on a depressive symptom after removing stress.
  • mice were in the open arm had a significant difference between a stressed example and a non-stressed example of the controls (0 ⁇ g/kg) in “the 1 week-administration groups after completion of stress”, but there was no significant difference between a stressed example and a non-stressed example of the 500 ⁇ g/kg administration examples (see FIG. 25 ), and the compound 8 exhibited an immediate therapeutic effect on an anxiety symptom after stress was removed.
  • the compound 8 exhibited a high therapeutic effect on an anxiety symptom after stress was removed.
  • FIGS. 29 and 30 show the results. Although doses are described in FIG. 29 , the compound 8 was not administered as described above, and mice corresponding to each of the administration groups administered with the compound 8 for 1 week after completion of stress are only shown.
  • the weight gaps of mice immediately after completion of stress had significant differences between a stressed example and a non-stressed example of the controls (0 ⁇ g/kg) and between stressed examples and non-stressed examples corresponding to respective administration groups, but in the 500 ⁇ g/kg administration examples after administrating the compound 8 for 1 week after completion of stress, there was no significant difference between a stressed example and a non-stressed example due to a therapeutic effect of the compound 8 on repressive and anxiety symptoms.
  • mice fed in one cage for 4 mice were first subjected to forced swimming for 15 minutes in the same manner as stress in Example 2 (behavior test of mice under stress) (1) described in the paragraph [0063] in the specification. Then, stress for 1 week using 3 kinds of cages was regarded as 1 cycle, and the stress was applied for 3 cycles (3 weeks) and chronic mild stress (CMS) was applied.
  • CMS chronic mild stress
  • the compound 8 and fluvoxamine were administered to mice immediately after stress in Exp. 1, 1 week after stress in Exp. 2, and 2 weeks after stress in Exp. 3, respectively, and tail suspension tests were carried out on the respective test groups.
  • the compound 8 was adjusted in concentration so as to have each of the doses of 20, 100 and 500 ⁇ g/kg and fluvoxamine was adjusted in concentration so as to have a dose of 1000 ⁇ g/kg, by dissolving in 0.1% DMSO, and each dose of the compound 8 and fluvoxamine were intraperitoneally injected to mice once per day from the time immediately after stress. Further, to 7-week-old male ddY strain mice fed in one cage for 4 mice without stress, the compound 8 and fluvoxamine were administered to carry out the tail suspension tests in the same manner as the stressed mice.
  • FIG. 31 show the result. A significance test was performed in a Student's t-test (*).
  • FIG. 31A shows an evaluation method of the behavior test (behavior assessment).
  • FIG. 31B shows immobility times of the mice. “DAEE” denotes the compound 8 and “Flu” denotes fluvoxamine.
  • FIG. 31B reveals that the compound 8 had an effect in a dose of 500 ⁇ g/kg in Exp. 2 (1 week after stress) but an effect could not be recognized with fluvoxamine. An effect of fluvoxamine was recognized only in Exp. 3 (2 weeks after stress). The results found that the compound 8 was excellent in an effect on a depressive symptom.
  • the voluntary alternation behavior test (Y-maze test) is one kind of a behavior test using a Y-shaped maze constituted with three arms. First, a mouse is placed on the tip of one arm out of the three arms, letting the mouse freely explore in the maze over 8 minutes, and arms where the mouse transferred are recorded in order. Then, the number of times of transferring to each arm (total arm selection number (total arm entries)) and the number of sequentially selecting three different arms (number of alternation behavior (number of spontaneous behavior)) are counted.
  • TMT Trimethyltin
  • the voluntary alternation tests were performed on 1) test groups to which the compound 8 was singly administered and 2) test groups to which TMT and the compound 8 were administered.
  • the compound 8 was dissolved in 0.1% DMSO to adjust a concentration so as to have each of the doses of 100 and 500 ⁇ g/kg and intraperitoneally injected to 6 mice in every administration example each in a dose of 0.25 mL.
  • 0.25 mL of a phosphoric acid buffer containing 0.1% DMSO was intraperitoneally injected in each time.
  • the voluntary alternation tests were performed on each of the administration groups after the elapse of 2 hours from intraperitoneal administration.
  • TMT (2 mg/kg weight) was intraperitoneally administered to a mouse, and the compound 8 was intraperitoneally administered in the same manner as the test groups in which the compound 8 was singly administered after 2 days have passed, and the voluntary alternation test (Y-maze test) was performed after the elapse of 2 hours.
  • FIG. 32 show the results. Significance tests were performed in a Turkey's test (*, ##) and a Student's t-test (++). “DAEE” denotes the compound 8.
  • FIG. 32B the total arm entries had no difference among respective test groups, which means that there was no difference in motor functions of the respective test groups.
  • FIG. 32A reveals that, in the test examples in which TMT and the compound 8 were administered at the same time, administration of the compound 8 suppressed decrease in the voluntary alternation behaviors that significantly decreased due to TMT treatments.
  • the compound 8 was singly administered, the voluntary alternation behaviors significantly increased due to administration of the compound 8, and thus, the compound 8 can impart resistivity against neurotoxicity of TMT to suppress declined memory and learning abilities and to promote the memory and leaning abilities of mice.
  • the compound 8 is considered to have an activity of improving memory and learning abilities by further increasing general functions of the hippocampus. Such an activity is considered to give a suppressive effect also on declined nervous functions due to an amyloid ⁇ peptide in Alzheimer's disease.
  • the novel object recognition test is a method of evaluating memory and learning abilities from behaviors after showing a “familiar object” and a “novel object” to mice, utilizing the fact that the mice take exploration behaviors (behaviors such as coming closer to or smelling an object) when they find the “novel object”.
  • the compound 8 was dissolved in 0.1% DMSO to adjust a concentration so as to have each dose of 100 and 500 ⁇ g/kg and intraperitoneally injected to 6 mice in every administration example each in a dose of 0.25 mL.
  • 0.25 mL of a phosphoric acid buffer containing 0.1% DMSO was intraperitoneally injected.
  • the compound 8 was administered to mice and the novel object recognition test was performed after 2 hours. That is, a mouse was put in a place where two identical objects were present for 15 minutes to let the mouse memorize the two objects (these two objects will be “familiar objects”).
  • FIG. 33 show the results. Significance tests were performed in a Student's t-test (*) and a Turkey's test (##). “DAEE” denotes the compound 8.
  • FIG. 33A shows time for the mice to explore “familiar objects” and “novel objects” (exploration time).
  • FIG. 33B shows recognition indices. The recognition indices are expressed by Y/X+Y assuming that a time for exploring the “familiar objects” is X and a time for exploring the “novel objects” is Y. It was found from FIG. 33B that since the recognition indices of the “novel objects” became high in examples to which the compound 8 was administered, the compound 8 had an activity of enhancing memory and learning abilities of a healthy animal. Such an activity is considered to give a suppressive effect also on declined nervous functions due to an amyloid ⁇ peptide in Alzheimer's disease.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US12/678,671 2007-09-19 2008-09-18 Agent having neurotrophic factor-like activity Abandoned US20100204498A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007242563 2007-09-19
JP2007-242563 2007-09-19
PCT/JP2008/066812 WO2009038110A1 (ja) 2007-09-19 2008-09-18 神経栄養因子様作用剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/066812 A-371-Of-International WO2009038110A1 (ja) 2007-09-19 2008-09-18 神経栄養因子様作用剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/439,058 Division US8557864B2 (en) 2007-09-19 2012-04-04 Agent having neurotrophic factor-like activity

Publications (1)

Publication Number Publication Date
US20100204498A1 true US20100204498A1 (en) 2010-08-12

Family

ID=40467920

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/678,671 Abandoned US20100204498A1 (en) 2007-09-19 2008-09-18 Agent having neurotrophic factor-like activity
US13/439,058 Expired - Fee Related US8557864B2 (en) 2007-09-19 2012-04-04 Agent having neurotrophic factor-like activity

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/439,058 Expired - Fee Related US8557864B2 (en) 2007-09-19 2012-04-04 Agent having neurotrophic factor-like activity

Country Status (4)

Country Link
US (2) US20100204498A1 (de)
EP (2) EP2457567B1 (de)
JP (1) JP5447954B2 (de)
WO (1) WO2009038110A1 (de)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013073973A1 (en) 2011-11-16 2013-05-23 Technix Industries Limited Bitumen cutback agents
EP2861226A1 (de) * 2012-06-15 2015-04-22 Vitaflo International Ltd. Ernährungsprodukt
US20160075631A1 (en) * 2014-09-15 2016-03-17 Elevance Renewable Sciences, Inc. Low-Toxicity Olefinic Ester Compositions and Methods of Using the Same
US9649288B2 (en) 2009-09-30 2017-05-16 The Nisshin Oillio Group, Ltd. Inhibitor of visceral fat loss in Parkinson's disease patients
US11535774B2 (en) 2021-03-08 2022-12-27 Technix EnviroCutter IP Limited Bitumen cutback compositions and methods of use thereof

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011136948A (ja) * 2009-12-28 2011-07-14 Nisshin Oillio Group Ltd うつ病又はうつ状態の予防又は治療用油脂組成物
CN103189350B (zh) * 2010-11-02 2016-04-27 公益财团法人名古屋产业科学研究所 反式-2-癸烯酸衍生物和含有其的药物
GB201020133D0 (en) * 2010-11-26 2011-01-12 Royal Holloway & Bedford New College Therapeutic use of compounds
AU2012211854A1 (en) 2011-01-31 2013-08-08 Nagoya Industrial Science Research Institute Prophylactic or therapeutic drug for peripheral neuropathy caused by anticancer agent
WO2012105477A1 (ja) 2011-01-31 2012-08-09 日本臓器製薬株式会社 鎮痛剤
JP6285352B2 (ja) * 2012-03-26 2018-02-28 飯沼　宗和 ３−デセン酸誘導体およびその用途
JP2013241408A (ja) * 2012-04-27 2013-12-05 Nagoya Industrial Science Research Institute トランス−２−デセン酸誘導体を含有する医薬
RU2602810C2 (ru) 2012-04-27 2016-11-20 Ниппон Дзоки Фармасьютикал Ко., Лтд. Производное транс-2-деценовой кислоты и содержащее его лекарственное средство
JPWO2013161994A1 (ja) 2012-04-27 2015-12-24 日本臓器製薬株式会社 鎮痛剤
JP6261564B2 (ja) * 2013-03-15 2018-01-17 アピ株式会社 ４−ハイドロパーオキシ−トランス−２−デセン酸誘導体及びこれを含有する医薬
KR102496390B1 (ko) 2014-06-06 2023-02-03 디킨 유니버시티 신경발달 질환 및 장애의 치료 방법
JP6669761B2 (ja) 2015-02-20 2020-03-18 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 不安神経症を治療するための中鎖脂肪酸及びそれらのトリグリセリド
JP6801704B2 (ja) * 2016-02-15 2020-12-16 小野薬品工業株式会社 ヘキサデセン酸誘導体
AU2018250864B2 (en) * 2017-04-10 2024-01-11 Ucl Business Ltd Composition for use in the treatment of epilepsy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007217311A (ja) * 2006-02-14 2007-08-30 Okayama Univ 神経細胞分化誘導剤

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2496270A (en) * 1946-02-09 1950-02-07 Synergistics Inc Skin dressings with fugitive colors
JPS58135878A (ja) 1981-09-22 1983-08-12 Suntory Ltd 新規アイラントン誘導体及びその製造法
US4560785A (en) 1983-03-02 1985-12-24 Ss Pharmaceutical Co., Ltd. Phenylacetic ester derivatives and process for preparing the same
JPS59161331A (ja) * 1983-03-02 1984-09-12 Ss Pharmaceut Co Ltd 新規なフェニル酢酸エステル誘導体
EP0632008B1 (de) 1993-06-01 1998-02-04 Ono Pharmaceutical Co., Ltd. Pentansäurederivate
JPH07173166A (ja) * 1993-11-05 1995-07-11 Takeda Chem Ind Ltd Ｔａｎ−１６０７ａ誘導体、その製造法および用途
JP3337615B2 (ja) * 1997-03-03 2002-10-21 花王株式会社 アルコールの製造方法
US6652866B1 (en) * 1997-10-14 2003-11-25 David W. Hertha Method for treating diseases of fungal, yeast, and prion protein etiology
US20030153541A1 (en) 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
US6576660B1 (en) 1997-10-31 2003-06-10 Arch Development Corporation Methods and compositions for regulation of 5-α-reductase activity
US6696484B2 (en) 1997-10-31 2004-02-24 University Of Chicago Office Of Technology And Intellectual Property Method and compositions for regulation of 5-alpha reductase activity
JP2003113085A (ja) 1998-04-23 2003-04-18 Takeda Chem Ind Ltd 神経栄養因子様作用剤
JP2000007568A (ja) 1998-04-23 2000-01-11 Takeda Chem Ind Ltd 神経栄養因子様作用剤
US20060025393A1 (en) 1999-04-30 2006-02-02 Shutsung Liao Steroid derivatives
AU775630B2 (en) 1999-04-30 2004-08-05 Arch Development Corporation Steroid derivatives
WO2001010447A1 (en) * 1999-08-05 2001-02-15 Tamara Stipcevic Use of rhamnolipids in wound healing, treatment and prevention of gum disease and periodontal regeneration
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
JP2005508281A (ja) 2001-02-08 2005-03-31 ザ ユニバーシティー オブ シカゴ ステロイド誘導体
JP2004533493A (ja) * 2001-02-26 2004-11-04 ザ プロクター アンド ギャンブル カンパニー 改善された安定性を有し、泡立ちが少ないアロマ送達組成物
US7078396B2 (en) 2001-05-03 2006-07-18 Arch Development Corporation Method of treating disorder related to high cholesterol concentration
US20070197484A1 (en) 2001-05-03 2007-08-23 Ching Song Method of treating disorder related to high cholesterol concentration
PT1392713E (pt) 2001-05-03 2008-01-25 Univ Chicago ''agonistas de receptores x hepáticos''
JP2003261545A (ja) 2001-12-28 2003-09-19 Takeda Chem Ind Ltd 神経栄養因子産生・分泌促進剤
US20060069104A1 (en) 2002-04-10 2006-03-30 Toshio Matsuda Neurotrophic factor production accelerator
WO2005032535A1 (ja) 2003-10-03 2005-04-14 Ono Pharmaceutical Co., Ltd. 神経再生促進剤
EP1848541A4 (de) * 2005-02-07 2013-01-16 Pharmalight Inc Verfahren und vorrichtung zur ophthalmischen verabreichung von pharmazeutischen wirksstoffen
FR2894577B1 (fr) * 2005-12-14 2008-02-22 Fabre Pierre Dermo Cosmetique Nouveaux composes polyinsatures, leur procede de preparation et les compositions les contenant.
EP2249823A4 (de) * 2008-02-15 2011-05-18 Us Gov Health & Human Serv Octansäure-formulierungen und behandlungsverfahren damit

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007217311A (ja) * 2006-02-14 2007-08-30 Okayama Univ 神経細胞分化誘導剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JP2007-217311, Aida E. et al., Nerve Cell Differentiation Inducer, English Abstract 1 page *
Suleymanian, M. A. et al., The effects of short-chain fatty acids on the neuronal membrane functins of Helix pomatia. I. Electrical Properties, 1986, Cellular and Molecular Neurobiology, vol. 6, no. 2, pp 151 - 163 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9649288B2 (en) 2009-09-30 2017-05-16 The Nisshin Oillio Group, Ltd. Inhibitor of visceral fat loss in Parkinson's disease patients
CN104024355A (zh) * 2011-11-16 2014-09-03 泰克尼克斯工业有限公司 沥青稀释剂
WO2013073973A1 (en) 2011-11-16 2013-05-23 Technix Industries Limited Bitumen cutback agents
EP2780427A4 (de) * 2011-11-16 2015-09-02 Technix Ind Ltd Bitumenabbaumittel
EP2861226B1 (de) * 2012-06-15 2022-11-02 Vitaflo International Ltd. Ernährungsproduct enthaltend decansäure und octansäure
US11344522B2 (en) 2012-06-15 2022-05-31 Vitaflow (International) Ltd Nutritional product
AU2021202459B2 (en) * 2012-06-15 2022-07-21 Ucl Business Plc Nutritional product
EP2861226A1 (de) * 2012-06-15 2015-04-22 Vitaflo International Ltd. Ernährungsprodukt
EP4162934A1 (de) * 2012-06-15 2023-04-12 Vitaflo International Ltd. Ernährungsprodukt
AU2022253500B2 (en) * 2012-06-15 2024-05-02 Ucl Business Plc Nutritional product
EP4371612A3 (de) * 2012-06-15 2024-07-31 Vitaflo International Ltd. Ernährungsprodukt
US20160075631A1 (en) * 2014-09-15 2016-03-17 Elevance Renewable Sciences, Inc. Low-Toxicity Olefinic Ester Compositions and Methods of Using the Same
US10358409B2 (en) * 2014-09-15 2019-07-23 Elevance Renewable Sciences, Inc. Low-toxicity olefinic ester compositions and methods of using the same
US11535774B2 (en) 2021-03-08 2022-12-27 Technix EnviroCutter IP Limited Bitumen cutback compositions and methods of use thereof

Also Published As

Publication number Publication date
EP2457567A1 (de) 2012-05-30
WO2009038110A1 (ja) 2009-03-26
JPWO2009038110A1 (ja) 2011-01-06
EP2204172A4 (de) 2010-09-22
EP2204172A1 (de) 2010-07-07
US20120264959A1 (en) 2012-10-18
US8557864B2 (en) 2013-10-15
EP2457567B1 (de) 2015-12-30
JP5447954B2 (ja) 2014-03-19

Similar Documents

Publication Publication Date Title
US8557864B2 (en) Agent having neurotrophic factor-like activity
US8188146B2 (en) Highly purified ethyl EPA and other EPA derivatives
JP2010511616A (ja) 水素化ピリド（４，３−ｂ）インドール（異性体）に基づいた認知機能および記憶を改善するための手段、当該手段に基づいた薬理学的手段、および当該手段の使用のための方法
US20180125818A1 (en) Methods and compositions for treating schizophrenia
JP7025212B2 (ja) 炎症性、変性及び神経変性疾患の治療のための化合物、組成物及び方法
EP2636666B1 (de) Trans-2-decensäurederivat und diese enthaltende arzneimittel
JP5590676B2 (ja) Ｐｅｒ３ｖｎｔｒ遺伝子型に基づく睡眠パラメータ及び睡眠誘導化合物に対する応答の予測
JP2020097580A (ja) 新規プラズマローゲン誘導体
JP2017502059A (ja) 製剤および医薬組成物
US10905663B2 (en) Treatment of demyelinating disorders
Redensek et al. Expression and detrimental role of hematopoietic prostaglandin D synthase in spinal cord contusion injury
WO2017062924A1 (en) Dosing regimens of pkc activators
CN110869015B (zh) 用于治疗神经炎性紊乱的有机小分子
EP4236774A1 (de) Verfahren zur behandlung und prävention neurodegenerativer erkrankungen mit hgf-aktivierenden verbindungen
ES2395120T3 (es) Combinación de pemirolast y ramotrobán para su uso en el tratamiento de transtornos inflamatorios
WO2018187647A1 (en) Methods and compositions for treatment of neurological diseases, disorders, or conditions
JP2024523589A (ja) アンジオテンシン及びその類似体の投与によるシナプス形成の誘導方法
US20210379061A1 (en) Balipodect for treating or preventing autism spectrum disorders
EP4147701A1 (de) Antidepressivum/anxiolytisches arzneimittel mit pac1-rezeptorantagonist
KR19980702116A (ko) 종양 괴사 인자 억제용 제약 제제
EP3567025A1 (de) Halogenierte ester von cyclopropanierten ungesättigten fettsäuren zur verwendung bei der behandlung neurodegenerativer erkrankungen
Ahmad et al. Role of the L-PGDS-PGD
JPWO2014142276A1 (ja) ４−ハイドロパーオキシ−トランス−２−デセン酸誘導体及びこれを含有する医薬

Legal Events

Date Code Title Description
AS Assignment

Owner name: NAGOYA INDUSTRIAL SCIENCE RESEARCH INSTITUTE, JAPA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:IINUMA, MUNEKAZU;FURUKAWA, SHOEI;REEL/FRAME:024098/0150

Effective date: 20100315

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION